Publicaciones en colaboración con investigadores/as de Technical University Munich (26)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717

  3. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020

2022

  1. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022

    Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865

  2. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  5. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1953-1963

  6. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1986-1998.e2

2021

  1. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

    HemaSphere, Vol. 5, Núm. 11, pp. E646

2020

  1. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151

  2. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts

    Theranostics, Vol. 10, Núm. 23, pp. 10743-10768

  3. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

    Journal of Allergy and Clinical Immunology, Vol. 146, Núm. 2, pp. 300-306

2019

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  2. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

    The Lancet Haematology, Vol. 6, Núm. 12, pp. e638-e649

  3. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1125-1133.e1

  4. The Big Data Sjögren consortium: A project for a new data science era

    Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23

2018

  1. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

2017

  1. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future

    Cancer Research, Vol. 77, Núm. 6, pp. 1261-1270

2016

  1. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; The American Academy of Allergy, Asthma & Immunology; And the European Academy of Allergology and Clinical Immunology

    Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 1, pp. 35-45